Manufacturing

Feliza Mirasol is the science editor for 

Articles

CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.

CordenPharma Launches New LNP Starter Kits for mRNA Formulation

Under a new collaboration, Lonza and Oxford Nanopore aim to commercialize a CGMP-validated test for advanced analysis of mRNA products.

Lonza and Oxford Nanopore Partner on mRNA Analytics

John Lewis, PhD, is CEO of Entos Pharmaceuticals.

Collaboration is a key component to achieving long-term success with genetic medicines.

Risks and Rewards of Investing in RNA-based Genetic Medicine Manufacturing

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

PharmTech Europe discusses technology that enables the “democratization” of mRNA manufacturing with Scott Ripley, general manager, Nucleic Acid Therapeutics and Precision Nanosystems, Cytiva, at the 11th International mRNA Health Conference in Berlin, Germany.

Democratizing GMP Manufacturing for the New Therapeutic Pipeline

In part two of an interview with Thomas Langenickel, MD, chief medical officer at Ethris, Langenickel highlights the challenges in developing mRNA therapeutics for pulmonary diseases.

mRNA Advances Allow Drug Development Focus on Rare Diseases (Part Two)

Andy Geall, co-founder and chief development officer at Replicate Bioscience continues the discussion on the development history of mRNA therapeutics.

Discussing the Origins of the mRNA Therapeutics Field (Part Two)

Andy Geall, co-founder and chief development officer at Replicate Bioscience, discusses the historical context and buildup of the mRNA therapeutics field.

Discussing the Origins of the mRNA Therapeutics Field (Part One)

Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation discusses the analytical and downstream purification challenges of oligonucleotides.

Discussing Oligonucleotide Challenges in Analytics and Purification (AAPS PharmSci 360)

Under this agreement, Acuitas Therapeutics’ LNP technology platform will be transferred to BIOVECTRA for use in manufacturing mRNA-based therapies.

BIOVECTRA in Tech Transfer Agreement with Acuitas Therapeutics for LNP Delivery System

With the two new GMP-grade mRNA manufacturing sites in Germany, MilliporeSigma can now offer fully integrated mRNA services.

Manufacturing, Nucleic Acids